Does the current apixaban dosing strategy adequately fit and ensure safety in Korean patients with atrial fibrillation?
作者信息
Kim Bohyun
机构信息
Department of Laboratory Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
出版信息
Blood Res. 2025 Sep 8;60(1):50. doi: 10.1007/s44313-025-00103-4.
Abstract
摘要
相似文献
1
Does the current apixaban dosing strategy adequately fit and ensure safety in Korean patients with atrial fibrillation?
Blood Res. 2025 Sep 8;60(1):50. doi: 10.1007/s44313-025-00103-4.
2
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results.
Eur Heart J Cardiovasc Pharmacother. 2025 Aug 12;11(5):403-411. doi: 10.1093/ehjcvp/pvaf018.
3
Effectiveness and Safety of Edoxaban Compared With Apixaban in Elderly Patients With Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study.
Stroke. 2024 May;55(5):1161-1170. doi: 10.1161/STROKEAHA.123.045098. Epub 2024 Mar 21.
4
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.
N Engl J Med. 2024 Jan 11;390(2):107-117. doi: 10.1056/NEJMoa2310234. Epub 2023 Nov 12.
5
Real-world apixaban concentration in Korean patients with atrial fibrillation.
Blood Res. 2025 Jul 7;60(1):39. doi: 10.1007/s44313-025-00089-z.
6
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22.
7
Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.
Clin Pharmacokinet. 2025 Feb;64(2):307-321. doi: 10.1007/s40262-025-01476-6. Epub 2025 Jan 24.
8
Effectiveness and Safety of Dose-Specific DOACs in Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Cardiovasc Ther. 2025 Jan 6;2025:9923772. doi: 10.1155/cdr/9923772. eCollection 2025.
9
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Int J Cardiol. 2016 Feb 1;204:88-94. doi: 10.1016/j.ijcard.2015.11.084. Epub 2015 Nov 17.
10
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.
JAMA Cardiol. 2025 Mar 26. doi: 10.1001/jamacardio.2025.0277.
本文引用的文献
1
Real-world apixaban concentration in Korean patients with atrial fibrillation.
Blood Res. 2025 Jul 7;60(1):39. doi: 10.1007/s44313-025-00089-z.
2
Back to basics: the coagulation pathway.
Blood Res. 2024 Oct 28;59(1):35. doi: 10.1007/s44313-024-00040-8.
3
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
4
The relationship between DOAC levels and clinical outcomes: The measures tell the tale.
J Thromb Haemost. 2020 Dec;18(12):3163-3168. doi: 10.1111/jth.15104. Epub 2020 Oct 19.
5
Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial.
TH Open. 2017 Dec 12;1(2):e139-e145. doi: 10.1055/s-0037-1613679. eCollection 2017 Jul.
6
Global rising trends of atrial fibrillation: a major public health concern.
Heart. 2018 Dec;104(24):1989-1990. doi: 10.1136/heartjnl-2018-313350. Epub 2018 Jun 15.
7
Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study.
Eur Heart J. 2017 May 14;38(19):1473-1479. doi: 10.1093/eurheartj/ehw613.
8
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
Thromb Haemost. 2014 Feb;111(2):240-8. doi: 10.1160/TH13-06-0470. Epub 2013 Oct 31.
9
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Br J Clin Pharmacol. 2013 Nov;76(5):776-86. doi: 10.1111/bcp.12106.
Zotero 插件